UCBJY : Summary for UCB ADR - Yahoo Finance

U.S. Markets closed


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
38.35-0.05 (-0.13%)
At close: 3:15PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close38.40
Bid0.00 x
Ask0.00 x
Day's Range38.35 - 38.35
52 Week Range29.20 - 41.60
Avg. Volume909
Market Cap7.24B
PE Ratio (TTM)26.12
Earnings DateN/A
Dividend & Yield0.63 (1.65%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire14 days ago

    UCB Launches Wellness 4U, an Innovative and Comprehensive Health and Wellness Program for Patients with Immunologic Diseases

    ATLANTA, March 15, 2017 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatments and research, has launched Wellness 4U™, an insights-driven health and wellness program that is dedicated to promoting healthier lifestyles. Wellness 4U is a multi-channel health and wellness program that utilizes several initiatives aimed to elevate patient outcomes beyond therapeutic support for people living with immunologic disorders and their healthcare professionals. Key Wellness 4U programs include a Wellness 4U Activity Tracker, a health outcomes research collaboration with the IBD Support Foundation, a national wellness education panel speaker event series addressing the entire care team and a nurse practitioner/physician's assistant educational initiative.

  • PR Newswire23 days ago

    First CIMZIA® (certolizumab pegol) Study of Its Kind Showed Minimal to No Transfer of Drug from Mother's Plasma to Breast Milk

    BRUSSELS, March 6, 2017 /PRNewswire/ -- Today UCB announced results from the CRADLE study, the first lactation study designed to evaluate CIMZIA® (certolizumab pegol) concentrations in human mature breast milk and to estimate the average daily infant dose of the drug in maternal breast milk, in accordance with guidance from the US Food & Drug Administration. The study used a bioanalytical assay specifically designed for CIMZIA, offering significantly improved sensitivity and specificity over previously used plasma assays. The reported results indicate minimal to no transfer of CIMZIA into breast milk, a minimal average daily infant dose, and a relative infant dose, considered to be in the acceptable range for breastfeeding.

  • UCB SA :UCBJY-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017
    Capital Cube28 days ago

    UCB SA :UCBJY-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017

    Categories: Yahoo Finance Get free summary analysis UCB SA reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of UCB SA – Shire PLC Sponsored ADR, Amgen Inc., Pfizer Inc., Biogen Inc. and Novartis AG Sponsored ADR (SHPG-US, AMGN-US, PFE-US, BIIB-US and NVS-US) that have also reported for ... Read more (Read more...)